Search

Search Constraints

You searched for: Author/Creator Fries, W.

Search Results

1. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (September 2021)

2. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021)

4. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020)

5. OC.02.5 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART1. Issue 2 (15th March 2018)

6. OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety. (15th March 2017)

7. OC.09.6 PERFORATING CROHN'S DISEASE AND EXTENSIVE COLITIS AS RISK FACTORS FOR INCIDENT CANCER: A MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 6 YEARS. (25th March 2019)

8. OC.10.3 THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE. (May 2022)

10. OC.11.1 INFLAMMATORY BOWEL DISEASE PHENOTYPE AS RISK FACTOR FOR CANCER IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY. (24th February 2016)